The GLUCARE consortium, which Safe Implant Technology is part of, has been awarded with funding from EUROSTARS to execute the ~€1,3M GLUCARE project aiming to develop a first-in-class implantable biosensor for continuous glucose monitoring (CGM) with long-term tolerability that will allow diabetic patients to benefit from accurate real-time blood glucose measurements for more effective diabetes management.
Safe Implant Technology has taken the first step towards MDR approval of our patented product GP5. Yesterday medical device implants were implanted, and preclinical trial will continue for the next 9 weeks to evaluate safety and efficacy of biocompatibility.
To make implantable medical devices safer, securer, and better for patients, Safe Implant Technology has developed and patented GP5.
Imagine having an implantable CGM that never has to be replaced or an abdominal mesh that won’t inflict pain. That’s what GP5 can do for patients across medical device types and brands.
Safe Implant Technology was founded with a vision to address the challenges posed by adverse immune reactions triggered by implantable medical devices. The company’s journey began with extensive research into understanding the underlying causes of these reactions. We established Mechanism of Action with GP5, a pioneering product that suppressed immunological responses, and form a proprietary surface coating that reduced complications and improved patient outcomes. Safe Implant Technology’s dedication to innovation and patient well-being led to seek regulatory approval and funding for the development of a generic surface coating for all implantable medical devices.
Safe Implant Technology envisions a future where implantable medical devices are safer, biocompatible, and offer improved outcomes for patients. We strive to be at the forefront of medical development, continuously innovating our generic surface coating GP5 to minimize immune reactions and ensure the long-term integrity and functionality of medical implants.
Safe Implant Technology’s mission is to develop and provide medical device surface coatings that decrease immune reactions, improve biocompatibility, and reduce post-operative complications. We aim to create a lasting impact on the field of medical technology, contributing to better patient experiences and ensuring the well-being of implant recipients worldwide. To achieve this mission, Safe Implant Technology seeks to establish a robust data foundation, conduct clinical studies, and obtain regulatory approval for the surface coating GP5, adhering to the highest standards of safety and effectiveness.
Safe Implant Technology are formed by a group of highly competent and specialized persons having more than 70 years of experience from life science, biotech and medtech industries.
